Mortality of MBL-producing Enterobacteriaceae Bacteremias with the Combined Use of Ceftazidime-avibactam and Aztreonam Vs. Other Active Antibiotics. a Multicenter Target Trial Emulation.

Launched by HOSPITAL ITALIANO DE BUENOS AIRES · May 14, 2024

Keywords

ClinConnect Summary

Patients will be categorized into two treatment groups for analysis:

CAZAVI + ATM treatment group and Other Active Antibiotics treatment group. As this study is retrospective, treatment group assignment will not be a randomized procedure. Allocation data will be collected from medical records as a dichotomous variable.

In the present study, allocation to CAZAVI + ATM or OAAs will depend on various factors such as drug availability, hospital costs, and medical criteria. Therefore, to ensure comparability among participant characteristics, baseline factors will be adjusted to mitigate indic...

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients aged 18 years or older
• • Confirmed bacteremia by MBL-type Carbapenemase-Producing Enterobacteriaceae (CPE)
• • Initiation of effective antibiotic therapy within 24 hours of identification of MBL-type CPE and within 96 hours of blood sample.
• Exclusion Criteria:
• * Bacteremia due to the following complicated infections:
• • Endocarditis or other endovascular infection without extractable focus.
• • Necrotizing fasciitis
• • Osteomyelitis or septic arthritis
• • Confirmed prostatitis
• • Non-drainable abscess or other unresolved infection requiring surgical intervention (e.g., cholecystitis)
• • Central nervous system infections
• • Empyema
• • Successive episodes of bacteremia by the same pathogen (with the same resistance profile) within the previous 60 days.
• • Polymicrobial bacteremias, not classified as contaminants.
• • Patients with documented allergy to beta-lactams.

Trial Officials